2-Part Seamless Part A (Phase 2)/ Part B (Phase 3) Randomized, DoubleBlind, Placebo-Controlled, Multicenter Study to Evaluate th

2-Part Seamless Part A (Phase 2)/ Part B (Phase 3) Randomized, DoubleBlind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

Abierta

Código protocolo: 230LE301
Código EudraCT: 2020-000727-40
Grupo de investigación: Reumatología
Servicio: Reumatología
Investigador/a principal: Cortes Hernandez, Josefina
Patología: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Fase: Fase III